36.18 +0.01 (0.03%)
After hours: 4:41PM EDT
|Bid||36.18 x 4000|
|Ask||36.28 x 3000|
|Day's range||36.03 - 36.54|
|52-week range||27.88 - 40.97|
|Beta (5Y monthly)||0.66|
|PE ratio (TTM)||14.32|
|Earnings date||27 Oct 2020|
|Forward dividend & yield||1.52 (4.18%)|
|Ex-dividend date||05 Nov 2020|
|1y target est||41.79|
The coronavirus pandemic neared a grim new milestone of 1 million deaths on Monday, as new diagnoses in the around the world continue to outpace a slowdown in the rate of fatalities.
Both of these biotechs have performed well this year, but should investors purchase shares of either?
Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ® (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight.1 This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.